cis-dichlorodiammineplatinum(II) with and without ICRF-159 in non-Hodgkin's lymphoma.
Two studies of cis-dichlorodiammineplatinum(II) (CDDP) were conducted. The single-agent phase II study revealed that three of ten patients with non-Hodgkin's lymphoma treated with CDDP alone achieved objective partial remission of 7-15 weeks' duration. Eight patients were treated with CDDP plus ICRF-159. None of these eight patients achieved an objected response. CDDP is active as a single agent in non-Hodgkin's lymphoma. The combination of CDDP plus ICRF-159 does not appear to be a promising salvage program for non-Hodgkin's lymphoma.